AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023Agreement and Plan of Merger • July 7th, 2023 • MorphImmune Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 29, 2023, by and among IMMUNOME, INC., a Delaware corporation (“Parent”), IBIZA MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and MORPHIMMUNE INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
SUPPORT AGREEMENTSupport Agreement • July 7th, 2023 • MorphImmune Inc. • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (this “Agreement”) is made as of June 29, 2023, by and between MORPHIMMUNE INC., a Delaware corporation (the “Company”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 7th, 2023 • MorphImmune Inc. • Pharmaceutical preparations • Washington
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation (the “Company’’), and Clay B. Siegall, Ph.D. (“Executive’’) (collectively referred to as the “Parties” or individually referred to as a “Party”).
